You must have noticed a series of changes your body goes through each month, during the menstrual cycle. You may experience ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

A normal menstrual cycle is defined as anything between 23 and 35 days.” During each monthly cycle, there are three distinct ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

follicular lymphoma (FL). The regulator accepted BLA resubmission after Regeneron achieved the FDA-mandated enrollment target for the Phase 3 confirmatory trial. In the previous submission ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

A regulatory decision on odronextamab for R/R FL is expected by July 30, 2025. The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...